drugset / Trial / NCT01758146

Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors

NCT01758146 ↗

RandomizedParallel-groupSingle-blindTreatment

Summary

To see the impact of obesity on the efficacy of adjuvant endocrine therapy with aromatase inhibitors in postmenopausal patients with early breast cancer in terms of: i) Locoregional recurrence ii) Distant metastases iii) Disease-free survival iv) Overall survival

Timeline

Start
2012-01
Primary completion
2020-01
Completion
2020-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 2.5 mg —
Comparator Tamoxifen Small molecule 20 mg —

Indications